Wellspect HealthCare, a global provider of continence care solutions, today announced the U.S. launch of the innovative ...

Wellspect HealthCare, a global provider of continence care solutions, today announced the U.S. launch of the innovative Suritytm Female External Catheter, a new non-invasive solution designed to ...

What Women Should Know About Preventing UTIs UTIs are one of the most common infections in the United States, with ...

Ovarian cancer is characterized by uncontrolled growth of cells in the ovaries. It can progress to another part of the body ...

When it comes to UTIs, anatomy is destiny. About half of all women will have at least one UTI in their lifetime. Only about 10% of men will have one.

Amman, Feb. 3 (Petra) – The Higher Population Council (HPC) revealed Tuesday that the rising trajectory of cancer diagnoses in the Kingdom is largely a function of rapid population growth and the ...

Makoko demolition leaves pregnant women displaced, sleeping in canoes without shelter or antenatal care, increasing risks of ...

Azenta, Inc. will announce fiscal first quarter 2026 earnings which ended on December 31, 2025, on Wednesday, February 4, 2026, before the market opens.The Company will host a conference call and live ...

Allschwil, Switzerland - February 06, 2026Idorsia Ltd (SIX: IDIA) announces the design of its FDA-agreed Phase 3 registration program for lucerastat in Fabry disease. Building on the robust biomarker ...

Discover how to identify and treat crystals in dog urine. Expert tips on diet changes, hydration, and prevention.

Designed to reinforce lucerastat as the first oral therapy suitable for all patients with Fabry disease, irrespective of their mutation type. The program is expected to support a potential regulatory ...

Data from up to 42 months of treatment reinforce lucerastat’s potential as a first-in-class oral substrate reduction therapy addressing key unmet needs across the Fabry populationThe company is ...